← All trials
NCT06389214
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 9, 2024
- Primary completion
- Jun 11, 2024
- Completion date
- Jun 11, 2024
- First posted
- Apr 29, 2024
- Last posted
- Jun 14, 2024
- Enrollment
- 132
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aldeyra Therapeutics, Inc.Lead sponsor
- Cliantha Research LimitedOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.